Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Antiviral Therapy

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0168-8278(08)60800-4PMID 18672537
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of the Bayer VERSANT HCV RNA 3.0 and the Roche COBAS Amplicor HCV Monitor, Version 2.0, assays in HCV genotype 4 infection

  2007influential reference
• Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection

  2007cited by this paper
• Pegylated interferon alpha‐2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response

  2007cited by this paper
• 8 24 Week treatment regimen with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in HCV genotype 1 or 4 ‘super-responders’

  2006cited by this paper
• Unique NS5b Hepatitis C Virus Gene Sequence Consensus Database Is Essential for Standardization of Genotype Determinations in Multicenter Epidemiological Studies

  2006cited by this paper
• Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.

  2006cited by this paper
• Peginterferon α-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response

  2005cited by this paper
• Pegylated interferon‐alpha 2b–ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis

  2005cited by this paper
• Response of Hepatitis C Genotype-4 Naïve Patients to 24 Weeks of Peg-Interferon-α2b/Ribavirin or Induction-Dose Interferon-α2b/Ribavirin/Amantadine: A Non-Randomized Controlled Study

  2005cited by this paper
• Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection

  2005cited by this paper
• Peginterferon α‐2b plus ribavirin compared with interferon α‐2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4

  2004cited by this paper
• Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin.

  2004cited by this paper
• Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

  2004cited by this paper
• Infection with Hepatitis C Virus Genotype 4 in the United States

  2004cited by this paper
• Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C Genotype 4

  2004cited by this paper
• First phase hepatitis c viral kinetics in previous nonresponders patients

  2003cited by this paper
• Viral Kinetics in Hepatitis C Virus: Special Patient Populations

  2003cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• Early viral kinetics on treatment with pegylated interferon‐α‐2a in chronic hepatitis C virus genotype 1 infection *

  2003cited by this paper
• First‐phase parameters in hepatitis C viral kinetics

  2002cited by this paper
• First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline

  2002cited by this paper
• Primary interferon resistance and treatment response in chronic hepatitis C infection

  2002cited by this paper
• Hepatitis C virus genotypes in Saudi Arabia.

  2002influential reference
• Hepatitis C viral dynamics: basic concept and clinical significance.

  2002cited by this paper
• Primary interferon resistance and treatment response in chronic hepatitis C infection.

  2002cited by this paper
• Changes in the prevalence of hepatitis C virus (HCV) genotype 4 in Calabria, Southern Italy.

  2002cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Establishment of new and replacement World Health Organization International Biological Standards for human interferon alpha and omega.

  2001cited by this paper
• Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study.

  2001influential reference
• Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

  2001cited by this paper
• Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response.

  2001cited by this paper
• Hepatitis C virus kinetics during induction and standard 3 times a week interferon-alpha therapy.

  2001cited by this paper
• Decline of hepatitis C virus load in serum during the first 24 h after administration of interferon-beta as a predictor of the efficacy of therapy.

  2001cited by this paper
• The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt.

  2000cited by this paper
• Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy

  1998cited by this paper
• Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

  1998cited by this paper
• Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.

  1998cited by this paper
• Route of infection, liver histology and response to interferon in patients with chronic hepatitis caused by genotype 4 HCV infection in a Western country.

  1998cited by this paper
• Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain.

  1997cited by this paper
• Variability of hepatitis C virus

  1995cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Hepatitis C virus genotype 4 therapy: progress and challenges

  2011cites this paper
• ORIGINAL ARTICLES—LIVER, PANCREAS, AND BILIARY TRACT Impact of IL28B Genotype on the Early and Sustained Virologic Response in Treatment-Naïve Patients With Chronic Hepatitis C

  2011cites this paper
• Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.

  2011cites this paper
• The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report

  2010cites this paper
• Hepatitis C genotype 4 therapy: increasing options and improving outcomes

  2009cites this paper
• Peginterferon and ribavirin in HCV: improvement of sustained viral response.

  2008cites this paper